Teni Boulikas

US Patent:

6511676, Jan 28, 2003

Filed:

Nov 5, 1999

Appl. No.:

09/434345

Inventors:

Teni Boulikas - Palo Alto CA 94306

International Classification:

A61K 9127

US Classification:

424450, 264 41, 264 43

Abstract:

A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.

US Patent:

7393478, Jul 1, 2008

Filed:

Jan 23, 2003

Appl. No.:

10/350470

Inventors:

Teni Boulikas - Palo Alto CA, US

Assignee:

Regulon, Inc. - Mountain View CA

International Classification:

A61K 9/127

US Classification:

264 4, 264 41, 264 43, 424450

Abstract:

A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.

US Patent:

20030072794, Apr 17, 2003

Filed:

Jun 8, 2001

Appl. No.:

09/876904

Inventors:

Teni Boulikas - Mountain View CA, US

International Classification:

A61K048/00
A61K009/127
C12N015/88

US Classification:

424/450000, 435/458000, 435/320100, 514/044000, 264/004000

Abstract:

A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

US Patent:

20090280164, Nov 12, 2009

Filed:

Jun 5, 2008

Appl. No.:

12/133634

Inventors:

Teni BOULIKAS - Palo Alto CA, US

International Classification:

A61K 9/127
A61K 33/24
A61K 38/20
A61K 38/21

US Classification:

424450, 424649, 424 852, 424 855, 424 857

Abstract:

A method for encapsulating cisplatin and other positively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers is disclosed. The liposomes are able to reach primary tumors and their metastases after intravenous injection to animals and humans. The encapsulated cisplatin has a high therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the encapsulated cisplatin with encapsulated doxorubicin or with other antineoplastic drugs are claimed to be of therapeutic value. Also of therapeutic value in cancer eradication are claimed to be combinations of encapsulated cisplatin with a number of anticancer genes including but not limited to p53, IL-2, IL-12, angiostatin, and oncostatin encapsulated into liposomes as well as combinations of encapsulated cisplatin with HSV-tk plus encapsulated ganciclovir.

US Patent:

20120183596, Jul 19, 2012

Filed:

Jul 2, 2010

Appl. No.:

12/830118

Inventors:

Teni Boulikas - Mountain View CA, US

International Classification:

A61K 31/7088
A61K 38/20
A61K 38/21
A61K 9/127
A61P 35/00

US Classification:

424450, 514 44 R, 514 44 A, 424 854, 424 852

Abstract:

A method is disclosed for encapsulating plasmids, oligonucleotides or negatively-charged drugs into liposomes having a different lipid composition between their inner and outer membrane bilayers and able to reach primary tumors and their metastases after intravenous injection to animals and humans. The formulation method includes complex formation between DNA with cationic lipid molecules and fusogenic/NLS peptide conjugates composed of a hydrophobic chain of about 10-20 amino acids and also containing four or more histidine residues or NLS at their one end. The encapsulated molecules display therapeutic efficacy in eradicating a variety of solid human tumors including but not limited to breast carcinoma and prostate carcinoma. Combination of the plasmids, oligonucleotides or negatively-charged drugs with other anti-neoplastic drugs (the positively-charged cis-platin, doxorubicin) encapsulated into liposomes are of therapeutic value. Also of therapeutic value in cancer eradication are combinations of encapsulated the plasmids, oligonucleotides or negatively-charged drugs with HSV-tk plus encapsulated ganciclovir.

US Patent:

60309563, Feb 29, 2000

Filed:

Oct 23, 1997

Appl. No.:

8/956994

Inventors:

Teni Boulikas - Palo Alto CA

International Classification:

C12N 1500
A01N 4304
C07H 2104
B32B 516

US Classification:

514 44

Abstract:

A method of treating cancer in a subject, by administering to the subject a combination of genes including wt p53, Pax5 and HSV-tk genes is disclosed. The method may involve subsequently treating the subject with ganciclovir.

US Patent:

58940600, Apr 13, 1999

Filed:

Jun 27, 1997

Appl. No.:

8/884025

Inventors:

Teni Boulikas - Palo Alto CA

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

A method of identifying a DNA sequence containing a human origin of replication (hORI) is disclosed. The method includes the steps of (A) providing fragments of human genomic DNA suitable for cloning into a bacterial plasmid, (B) ligating the fragments into a bacterial plasmid comprising (i) a bacterial origin of replication, (ii) a bacterial selection marker, and (iii) a mammalian selection marker, (C) transforming bacterial host cells with the plasmid, (D) selecting transformed bacterial host cells using the bacterial selection marker, (E) isolating plasmid DNA from the transformed bacterial host cells, (F) transfecting human cells with the isolated plasmid DNA, (G) selecting transfected human cells using the mammalian selection marker, (H) isolating extrachromosomal DNA from selected human cells, (I) digesting a suspension of the extrachromosomal DNA with a restriction endonuclease capable of cleaving methylated, but not unmethylated DNA, and (J) purifying undigested extrachromosomal DNA from the suspension.